Co-parnavel tab 0.625mg + 2mg 30 units 1 + 1


Co-parnavel tab 0.625mg + 2mg 30 units 1 + 1



Active substance:
1 tablet contains: – indapamide – 0.625 mg perindopril erbumine – 2,000 mg; 1 tablet contains: – indapamide – 1,250 mg, of perindopril erbumine – 4,000 mg.
Product form:
The tablets of 0.625 mg ± 2 mg and 1.25 mg plus 4 mg. 10, 20, 30 tablets in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50 or 100 tablets in banks of PET for drugs sealed with lids screw-with the control of the first opening or the system “push-turn” of polypropylene or polyethylene, or banks polymer of polypropylene for medicaments sealed with lids tensioned with the first control opening of polyethylene. One jar or 1, 2, 3, 4, 5 or 10 contour cell packages together with instructions for use placed in a cardboard box (pack). Equipment is allowed to 2 or 3 cartons (packs) in multipacks (transportation) of paperboard for consumer packaging.
Perindopril – Hypersensitivity to perindopril or other ACE inhibitors. – simultaneous use of aliskiren and aliskirensoderzhaschimi drugs in patients with diabetes or impaired renal function (glomerular filtration rate (GFR) of less than 60 ml / min / 1.73 m2). – Angioneurotic edema (Quincke’s edema) in history associated with taking an ACE inhibitor. – Hereditary / idiopathic angioedema. – Pregnancy. – The period of breastfeeding. – Age 18 years (effectiveness and safety have been established). Indapamide – Hypersensitivity to indapamide, other sulfonamide derivatives, severe renal failure (creatinine clearance (CC) of less than 30 ml / min), severe liver or hepatic encephalopathy, hypokalemia, pregnancy, breast-feeding, age of 18 years (insufficient data safety and efficacy). The simultaneous use of drugs that can cause arrhythmia type “pirouette”. Co-Parnavel – Hypersensitivity to the excipients included in the composition of the drug. – Simultaneous treatment with potassium-sparing diuretics, potassium and lithium drugs, and in patients with a high content of potassium in the blood plasma; – lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome, – Simultaneous treatment with drugs prolonging the QT interval – Bilateral renal artery stenosis or stenosis of the artery only functioning kidney. – Due to the lack of sufficient clinical experience drug Ko Parnavel not be used in patients on hemodialysis, and patients with untreated heart failure decompensation. – Age 18 years (effectiveness and safety have been established).
0.625 mg + 2mg
Essential hypertension (patients in whom combination therapy is shown).
pharmachologic effect
Pharmacological group:
Antihypertensive combined (angiotensin-converting enzyme (ACE) inhibitor + diuretic). ATC code S09VA04.
Pharmacological properties:
Ko Parnavel – a combined preparation comprising an ACE inhibitor – perindopril and thiazide diuretic – indapamide. A synergistic effect of perindopril and indapamide determines the pharmacological properties of the drug. Perindopril – ACE inhibitor, the mechanism of action of which is associated with inhibition of ACE activity, leading to a decrease in the formation of angiotensin II, having vasoconstrictor activity, as well as degrading bradykinin, which has vasodilatory action, to the inactive heptapeptide. As a result, perindopril reduces the secretion of aldosterone, renin activity increases in the blood plasma of feedback; long-term use decreases total peripheral vascular resistance (SVR), which is caused mainly by the action on blood vessels in the muscle and kidney. These effects were not accompanied by a delay of salts and liquids or the development of reflex tachycardia. Perindopril has therapeutic effect due to the active metabolite – perindoprilat. Other metabolites are pharmacologically inactive. Perindopril normalizes the functioning of the heart, helping to expand the veins (decreased preload) due to changes in the metabolism of prostaglandins and reduce systemic vascular resistance (afterload reduction). In chronic heart failure (CHF), perindopril reduces the filling pressure in the left and right ventricles of the heart, reduces peripheral vascular resistance, increases cardiac output and cardiac index increases, increases peripheral blood flow in the muscles.
Conditions of supply of pharmacies
Dosing and Administration
Inside, once a day, preferably in the morning before breakfast, without chewing, drinking plenty of fluids. The dose is adjusted individually for each patient depending on the patient’s condition and individual response to treatment. Doses are given for the ratio of perindopril / indapamide. The recommended starting dose – Table 1. Ko Parnavel drug (2 mg / 0,625 mg), 1 time per day. If after 1 month. the drug can not achieve adequate control of blood pressure, the dose should be increased to Table 1. Ko Parnavel formulation (4 mg / 1.25 mg), 1 time per day.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review